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Abstract
Gastric cancer is the second most common cause of cancer death worldwide. A large body of evidence supports a causal role of Helico-
bacter pylori in the majority of gastric malignancies. Great strides have been made in understanding the pathogenesis of this relationship,
but much remains to be learned. Moreover, because of the high prevalence of infection, the lack of deﬁnitive trials, and the challenges
of H. pylori treatment, there remains no consensus on the role of routine screening and treatment of this infection to prevent cancer.
This article reviews the current knowledge on H. pylori and gastric cancer and presents some of the clinical and public health challenges
associated with this pathogen.
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Introduction
Gastric cancer is the second leading cause of death due to
cancer worldwide. In 2002, 934 000 cases were recorded
(9% of new cancers) with 700 000 deaths [1]. Yet, despite
these daunting numbers, which, in part, are consequent to
increased human longevity, the rate of gastric cancer has
actually been declining from the early 20th Century onward.
The precipitous drop in incidence, particularly in industrial-
ized nations, has been the topic of extensive investigation.
Finally, the reason for this declining rate has now become
clear; it is a result of the diminishing prevalence of Helicobact-
er pylori infection, an organism that, until very recently, was
part of the normal ﬂora of humans.
Interest in H. pylori as a cause of cancer began after the
pioneering discoveries of Marshall and Warren in the 1980s
[2]. Prior to the discovery of the organism, it was known
that gastric adenocarcinomas typically arose in areas of gas-
tritis. When the relationship between H. pylori and chronic
gastritis was established, investigators began to take interest
in the causal role of H. pylori in gastric cancer. The ﬁrst stud-
ies to examine the association between H. pylori and gastric
cancer were ecological, comparing the regional prevalence of
H. pylori with the incidence of gastric cancer [3]. Sub-
sequently, numerous observational studies of diverse design
conﬁrmed these ﬁndings. In 1994, the International Agency
for Research on Cancer declared H. pylori to be a type I car-
cinogen, or a deﬁnite cause of cancer in humans [4].
We discuss the epidemiological and pathophysiological
data that led to the consensus that H. pylori is one of the
world’s most important causes of cancer.
Helicobacter pylori
H. pylori is a Gram-negative, spiral-shaped bacterium that is
characterized by its many unipolar ﬂagella, which give it
corkscrew-like motility, and its prodigious production of
urease. Unique among bacteria, it ﬁnds a niche in both the
antral and fundic mucosa of the stomach under the mucus
gel. The presence of infection is universally associated with
chronic and acute inﬂammation and, more variably, with
other gastric lesions, including lymphoid follicles, atrophic
gastritis and intestinal metaplasia. Treatment with antimi-
crobial agents causes inﬂammation to regress over time
[5]. With relapse of infection, the gastritis is again
observed [6].
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H. pylori is typically acquired during childhood and causes
lifelong infection thereafter [7]. Although previously almost
universal in humans, currently ‘only’ half of the world’s popu-
lation is infected with H. pylori. Transmission is largely from
person to person via the faecal–oral or the gastric–oral
route within families, particularly in settings of poor sanita-
tion and hygiene [8]. The prevalence of infection varies
worldwide, with continued hyper-endemicity in developing
countries but a markedly lower prevalence in developed
countries [9]. H. pylori is now rare in native-born and
middle- or upper-class children of Western Europe [10],
North America [11], Oceania [12] and Japan [13].
Epidemiological Links between Gastric
Cancer and H. pylori
Subsequent to its discovery in the early 1980s, over 1000
studies have been conducted on H. pylori and its association
with cancer, including observational studies (ecological, case–
control and cohort), clinical trials of H. pylori eradication,
pathological studies and animal models. The results have
been overwhelmingly in favour of a link between infection
and malignancy. Among the many observational studies in
humans, case–control studies indicate the lowest risk for
cancer (1.8-fold increase) [14]. It is now understood that
these studies underestimate the true risk due to loss of
H. pylori as the mucosa undergoes malignant transformation.
Nested case–control studies indicate higher relative risks in
meta-analyses [15]. However, the most compelling observa-
tional evidence of an association between H. pylori infection
and gastric cancer comes from longitudinal cohort studies. In
a large prospective trial conducted in Japan, 36 out of 1246
infected individuals developed gastric cancer compared to
none of 280 uninfected participants (inﬁnite OR) [16]. A pro-
spective study of 1225 Taiwanese patients conﬁrmed this
‘inﬁnite’ OR (p 0.015) [17].
Not all H. pylori are alike, however, and the epidemiologi-
cal story is complex. Individuals with antibodies to H. pylori’s
CagA protein (a marker for the more inﬂammatory and viru-
lent strain bearing a pathogenicity island of genes) have a
particularly high risk of cancer. A meta-analysis of studies
shows that CagA-positive strains increase the risk of noncar-
dia gastric cancer two-fold compared to CagA-negative
strains [18]. Moreover, gastric cancer, similar to H. pylori, is
heterogeneous, with two histological types predominating:
the intestinal-type and the diffuse type. Although H. pylori has
been linked to both histological types, CagA appears to
enhance the risk of the intestinal type that arises in the set-
ting of inﬂammation, atrophic gastritis and intestinal metapla-
sia, but not the risk of the diffuse type that appears to stem
from e-cadherin mutations [19].
Deﬁnitive experimental proof that H. pylori causes cancer
in humans lags behind the observational science, largely
because the studies are so difﬁcult to undertake. Random-
ized clinical trials of secondary cancer prevention through
H. pylori eradication require both a large number of subjects
and many years of follow-up [20]. To obviate these prob-
lems, a number of investigators have used gastric cancer pre-
cursors (i.e. multifocal atrophic gastritis and intestinal
metaplasia) as surrogates for measuring the effects of
H. pylori eradication on the malignant process. Overall, these
studies suggest improvement of pre-neoplastic lesions,
although the change is slow and not universally observed
[21]. Indeed, in some studies, continued progression of pre-
neoplastic conditions has been substantial despite H. pylori
eradication. Complicating matters further, the one random-
ized clinical trial concerning cancer prevention completed to
date did not show a signiﬁcant association between H. pylori
eradication and disease prevention, although there was a
trend towards beneﬁt, particularly in young patients without
pre-neoplastic conditions [22]. By contrast, a randomized,
open-label trial in 544 Japanese patients treated with endo-
scopic resection of early gastric cancer showed signiﬁcantly
lower rates of secondary, metachronous cancers in those
who received ‘adjuvant’ H. pylori eradication therapy com-
pared to those who did not (OR 0.35, 95% CI 0.16–0.78)
[23]. Again, not all treated patients beneﬁted. Thus, although
the experimental data in humans are thin, they do support
the notion that H. pylori causes cancer and that its treatment
provides some beneﬁt.
Based on the amalgam of observational and experiment
studies, the attributable risk of gastric cancer in the popula-
tion (i.e. the proportion of gastric cancer in the population
that would not occur were the H. pylori not to exist) has
been estimated to be 75% [24]. If this is accurate, H. pylori
would be responsible for as many as 5.5% of all
cancers, making it the leading infectious cause of cancer
worldwide and second only to smoking as a deﬁned cause of
malignancy.
Mechanisms of Carcinogenesis
Although mechanisms of H. pylori-induced carcinogenesis are
only beginning to be understood, inﬂammation is the most
commonly cited factor in the carcinogenic process. Inﬂamma-
tion is thought to induce cancer by increasing production of
free radicals [25], increasing apoptotic and necrotic epithelial
cell death [26] and augmenting cell proliferation [27]. To
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compound these pro-carcinogenic processes, H. pylori has
been noted to reduce DNA repair in vivo and in vitro [28].
The importance of inﬂammation as a risk factor is bolstered
by three complementary observations: ﬁrst, that the bacterial
strains that induce the most inﬂammation are most closely
linked to malignancy [29]; second, that pro-inﬂammatory
host cytokine polymorphisms increase cancer risk [30], and
third, that nonsteroidal anti-inﬂammatory agents appear to
decrease the risk of cancer [31].
Mechanisms other than inﬂammation have been posited
for H. pylori-related carcinogenesis. H. pylori directly inter-
acts with epithelial cells, resulting in protein modulation
and gene activation [32]. Strains that contain the pathoge-
nicity island of genes have a particularly intimate relation-
ship with the host. These strains produce a type IV
secretion system through which the CagA protein is
injected into gastric epithelial cells. There, the protein
becomes phosphorylated by members of the Sac family of
kinases, implicated in other malignancies. The phosphory-
lated CagA then activates the eukaryotic phosphokinase,
SHP2, as well as extracellular signal-regulated kinase (a
member of the mitogen-activated protein kinase family).
The pathogenicity island also results in a ‘hummingbird’ epi-
thelial phenotype, epithelial motility, loss of gap junctions,
and eventual epithelial cell death [33].
Most recently, much attention has been given to the rela-
tionship between H. pylori, stem cells and cancer. Some have
proposed that H. pylori preferentially damages parietal cells,
thereby altering the maturation process of epithelial stem
cells [34]. Others report that inﬂammation related to
H. pylori recruits peripheral- or bone-marrow derived stem
cells to the gastric mucosa, which then transform into the
malignant clone. The strongest evidence of this comes from
experiments performed by Houghton et al. [35], who identi-
ﬁed bone-marrow derived stem cells as the cells of malignant
origin in C57BL/6 mice. By contrast, Giannakis et al. [36]
report identifying H. pylori inside gastric stem cells. They fur-
ther observed that an isolate from a cancer patient had clo-
ser afﬁnity to gastric stem cells, causing more profound
regulation of cell function, than did an isolate from the same
patient 4 years before the cancer diagnosis, suggesting that
the organism evolved through crosstalk with the host epithe-
lium. This ‘endosymbiosis’ may be, in the end, a critical factor
in disease development.
Co-factors in Carcinogenesis
Although half of the world’s population is infected with
H. pylori, only a minority of individuals (estimated 1–2%) pro-
gress to gastric cancer over a lifetime. This percentage is
deceptively low, however, because children and young adults
are included in the lifetime risk assessment. When only mid-
dle-aged adults are considered, the risk of cancer appears
more substantial. For example, in prospective studies con-
ducted in Asia, between 3% and 6% of H. pylori-infected sub-
jects developed gastric cancer within a decade [16,37]. Yet,
worldwide, the great majority of adults infected with H. pylori
survive without ever suffering from malignancy. Unfortu-
nately, the reason some develop cancer and others do not is
incompletely understood.
As mentioned above, bacterial factors appear to play a
role in disease outcome. In addition to the pathogenicity
island previously mentioned, a vacuolating cytotoxin (VacA)
has been linked to malignancy. This protein has genotypes of
varying epithelial toxicity. The s1/mL vacA allele has been
particularly linked to epithelial damage and to carcinogenesis
[38]. The vacA alleles have varying global prevalence that can
explain, in part, the marked differences in the incidence of
gastric cancer noted worldwide [29]. Other microbial factors
that vary among strains and may affect the pathogenicity of
H. pylori include apurinic/apyrimidinic endonuclease-1, which
activates transcription factors and is involved in the DNA
repair of oxidative damage [39]; OipA, an outer membrane
protein linked to inﬂammation; and BabA which binds
H. pylori to Lewis blood group antigens [40].
After bacterial genetics, probably the single most impor-
tant factor inﬂuencing carcinogenesis is host genetics. Poly-
morphisms in the interleukin (IL)-1b and IL-1 receptor
antagonist are particularly well studied [41]. IL-1b acts as
both an inhibitor of gastric acid secretion and a pro-inﬂam-
matory cytokine, both of which would tend to enhance
carcinogenesis. Polymorphisms in tumour necrosis factor
and IL-10 have also been linked to intestinal-type cancer
[30], whereas IL-8 promoter polymorphisms have been
linked to diffuse-type cancer [42]. Human leukocyte antigen
polymorphisms have been variably linked to gastric cancer
[43]. In one of the largest study series to date, 520 H. pylor-
positive patients (330 with noncardia gastric cancer and
190 non-ulcer control patients) were evaluated for the
inﬂuence of genetic factors on gastric cancer susceptibility.
The results suggested that the combination of human leu-
kocyte antigen class II and IL-10-592A/C polymorphisms
affected the susceptibility to gastric cancer in a synergistic
manner [44].
There is limited evidence of associations between environ-
mental exposures and gastric cancer in the context of
H. pylori infection. A prospective study from Colombia
demonstrated that H. pylori eradication and increased
dietary vitamin C and b-carotene prevented progression of
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pre-neoplastic lesions to cancer [45]. Long-term follow-up of
this trial, however, showed that the dietary beneﬁts disap-
pear when participants are followed for a longer period of
time [46]. Increased consumption of salt may also increase
the risk of gastric cancer. In a study of 2476 participants,
followed prospectively for 14 years, there was a signiﬁcant
relationship between increased salt consumption and the
development of gastric cancer in subjects infected with
H. pylori [47]. Several studies have also demonstrated that
cigarette smoking ampliﬁes the H. pylori-associated risk of
cancer [48].
An intriguing area of interest is the impact of infection
with helminths on the outcome of H. pylori in humans. It has
been postulated that, by decreasing the Th1 inﬂammatory
response, helminthes could theoretically reduce gastric
inﬂammation and cancer incidence. This phenomenon has
been seen in some animal models of co-infection [49] and
has also been suggested in small human studies [50].
Cancer Prevention
Although there is strong agreement that H. pylori causes
cancer, there is little consensus on whether and when this
carcinogenic process can be reversed. The clinical trial of
pre-neoplastic lesions by Fukase et al. [23] suggests that
beneﬁts can come very late in the malignant process, even
after cancer has already begun. This conﬂicts with other
human data that demonstrate continued disease progres-
sion in many individuals after H. pylori eradication. More-
over, it conﬂicts with the randomized clinical trial of Wong
et al. [22] that revealed no beneﬁts of H. pylori treatment
in those with pre-neoplastic conditions. Thus, screening for
and treatment of H. pylori infection as a strategy for sec-
ondary prevention of gastric cancer remains controversial.
The controversy is ampliﬁed by data indicating beneﬁts by
preventing esophageal adenocarcinoma [51], asthma [52],
diarrhoea [53] and even tuberculosis [54]. These data addi-
tionally call into some question the advisability of creating
a vaccine.
Yet, despite the ongoing academic debate, several impor-
tant consensus groups have recommended screening and
treatment of those at highest risk of malignancy (i.e. those
with a family history of cancer, with prior gastric surgery, or
with documented atrophic gastritis) [55]. These same guide-
lines do not discourage broader screening based on individ-
ual choice. This last point conforms with the view of a
number of H. pylori experts who have strongly advocated
screening and treatment of wide swaths of the population.
Although this is an appealing strategy and numerous studies
have indicated it could be cost effective [56], there are
currently no screening and treatment programmes ongoing
outside of the research sphere.
A promising ﬁeld is the use of molecular testing to predict
clinical outcomes. Currently there is no reliable way to
identify, among individuals infected with H. pylori, those with
the highest risk of developing gastric cancer. Using
high-throughput proteomics, Khoder et al. [57] evaluated
129 H. pylori strains from individuals with gastric cancer or
duodenal ulcers. After identifying 18 statistically signiﬁcant
biomarkers, there were three proteins that predicted pro-
gression to cancer; these included a neutrophil-activating
protein NapA, a RNA-binding protein, and a DNA-binding
histone-like protein. These novel biomarkers could poten-
tially be used as diagnostic assays to predict the evolution to
gastric cancer. The usefulness of this approach in patients
without pre-cancerous lesions is not clear [58], but it is an
interesting avenue for future research.
Conclusions
H. pylori causes the majority of the world’s gastric cancers.
With this knowledge comes the power to potentially control
and eliminate this highly lethal disease. To date, however, we
have not yet reached a consensus on whether or not to
exterminate this microbe from the human host. It is possible
that the answer may vary for different populations at differ-
ent levels of risk of disease. In the absence of human inter-
vention, we are fortunate that H. pylori appears to be
disappearing from many human populations spontaneously.
With this natural experiment, we will undoubtedly glean fur-
ther data to inform us of our best approach worldwide to
infection and disease.
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